A dopamine receptor agonist for use in the treatment of erectile dysfunction. Submission of NDA for U.S. marketing approval pending completion of ongoing U.S. clinical trials. Product approved in the EU and is marketed as Ixense(tm). Mfg: TAP Pharmaceutical Products Inc. (formerly TAP Holdings), an Abbott Laboratories/Takeda Chemical Industries, Ltd.(Japan) joint venture. Source: PR Newswire - 05/04/99, 06/30/00; Pharmalicensing News - 06/01/01.